Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00812071 · ClinicalTrials.gov registry record · Phase 1

Phase 1B Study of RiVax, a Vaccine to Prevent the Toxic Effects of Ricin

A Phase 1 study of Healthy, sponsored by University of Texas Southwestern Medical Center.

Completed
Registry status
Phase 1
Development phase
30
Enrollment target
1
Study location

NCT00812071 is a Phase 1 study of Healthy that has completed, run by University of Texas Southwestern Medical Center. The registered enrollment target is 30 participants, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00812071, a Phase 1 study of Healthy, has completed, sponsored by University of Texas Southwestern Medical Center.

COMPLETED
Registry status
Phase 1
Development phase
30 participants
Enrollment target
1
Study location

Study Summary

Dose escalation study: 3 dose groups. 5 patients in each dose group, then 15 more patients in "best" group. 3 vaccinations in volunteers, at 0 6 and 16 weeks.

Conditions Studied

Interventions

  • BIOLOGICAL RiVax

Study Locations (1)

Virginia

  • Hampton Roads Center For Clinical Research - Chesapeake

Trial Details

FieldValue
Enrollment Target 30 participants
Start Date 2008-03
Est. Completion 2012-05
Phase Phase 1

What the Registry Record Tells You About NCT00812071

The ClinicalTrials.gov registry entry for NCT00812071 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (95% lower). The listed sponsor is University of Texas Southwestern Medical Center, which has 837 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Healthy appearing as the primary indexed condition, and to 1 intervention - of which RiVax is the first listed.

NCT00812071 reports 1 study location spanning 1 distinct geographic area - top geographies include Virginia.

Frequently Asked Questions

What is clinical trial NCT00812071 about?

NCT00812071 is a clinical study titled "Phase 1B Study of RiVax, a Vaccine to Prevent the Toxic Effects of Ricin". Dose escalation study: 3 dose groups. 5 patients in each dose group, then 15 more patients in "best" group. 3 vaccinations in volunteers, at 0 6 and 16 weeks.

What is the current status of trial NCT00812071?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2008-03. Estimated completion is 2012-05.

What conditions does trial NCT00812071 study?

This clinical trial studies the following conditions: Healthy.

What interventions are being tested in trial NCT00812071?

The interventions under investigation include: RiVax (BIOLOGICAL).

Who is sponsoring clinical trial NCT00812071?

This trial is sponsored by University of Texas Southwestern Medical Center, which has 837 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00812071 being conducted?

This trial has 1 study location across Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Healthy

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.